Artal Group S.A. Immuno Gen, Inc. Transaction History
Artal Group S.A.
- $214 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding IMGN
# of Institutions
8Shares Held
1.41MCall Options Held
0Put Options Held
0-
Pictet Asset Management Sa Geneva 73, V8721KShares$00.02% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC416KShares$03.65% of portfolio
-
Health Cor Management, L.P. New York, NY150KShares$00.7% of portfolio
-
Kellner Capital, LLC New York, NY69.2KShares$03.7% of portfolio
-
Leo Brokerage, LLC25KShares$00.05% of portfolio
About ImmunoGen, Inc.
- Ticker IMGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 220,712,992
- Description
- ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...